Evaxion A/S (EVAX) is a clinical-stage, Denmark-based biotechnology company that uses artificial intelligence to design immunotherapies and vaccines, led by its EVX-01 cancer vaccine program in a Phase 2b trial for advanced melanoma. Its shares trade as American Depositary Shares (ADSs) on the Nasdaq Capital Market. With the stock near $3, a move to a $12 price target would represent a roughly 300% advance — a very large move that hinges almost entirely on clinical execution and continued analyst conviction rather than near-term financials.
The $12 central target is calculated from four individually verified analyst price targets. H.C. Wainwright's Swayampakula Ramakanth holds a Buy with a $16 target, raised from $14 in September 2025 and reiterated in early 2026. Lake Street's Thomas Flaten rates the stock Buy with an $11 target, raised from $6 in October 2025. Edward Jones initiated coverage with a Buy and a $10 target in late October 2025, while JonesTrading also holds a Buy rating near the low end of the range at about $9. The four targets average roughly $11.50, which rounds to a clean central target of $12.
The approximate range of $9 to $16 is notably wide, reflecting genuine disagreement about how much the market should pay for a pre-revenue-stage, AI-enabled immunotherapy pipeline. The most bullish view, H.C. Wainwright's $16, effectively prices in meaningful clinical progress for EVX-01, while the lower targets embed more conservative assumptions about data timing, financing, and execution risk. Notably, all four firms lean positive, so there is no published bearish target in the current set — the disagreement is about magnitude, not direction.
The latest verified close is $3.00 (early November 2026), within a 52-week range of $2.71 to $6.92. Reaching $12 would require a roughly 300% gain, which is a very large move. The stock trades far below its 52-week high set around December 2025, and its market capitalization is only about $25 million — small even by clinical-stage biotech standards.
Financially, Evaxion reported trailing twelve-month revenue of roughly $7.5 million with a net loss and a diluted EPS of about -$1.00, and roughly $14 million in cash in the most recent quarter. That means the path to $12 cannot be driven by current earnings; it would have to come from re-rating on clinical data, partnership or licensing news, or a successful capital raise that removes near-term financing overhang. The company's own AI platform, which generated its revenue growth, is a differentiating narrative, but it does not yet translate into profitability.
Near $3.00, EVAX sits just above its 52-week low of $2.71, which now acts as the most important nearby support level; a decisive break below it would signal further downside. On the upside, the prior 52-week high around $6.92 represents a major resistance level that would need to be reclaimed before the stock could attempt a move toward double digits. Psychological levels at $5 and $10 may also act as intermediate hurdles. The current structure — trading near the bottom of a wide range after a steep decline — underscores that any move toward $12 would require a sustained trend reversal, not just a short-term bounce.
Analyst price targets for Evaxion typically reflect a roughly 12-month research horizon, though the wide $9-to-$16 range shows analysts weight near-term catalysts very differently. Investors should monitor EVX-01 Phase 2b data updates, upcoming quarterly results and any updated guidance on cash runway, new partnership or licensing announcements, and any revisions to analyst targets or ratings. Financing developments, including potential offerings, are equally important given the company's cash position.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap name like EVAX, these signals can help traders spot changing trends and momentum shifts more efficiently than manual chart review. Traders can use the tool to discover opportunities, monitor existing positions, and react to emerging patterns with greater speed.
Can Evaxion reach $12? The question depends far more on clinical milestones than on anything in the income statement. The $12 central target, derived from four Buy-rated analyst targets ranging from about $9 to $16, implies a roughly 300% advance from the current $3.00 price — a very large move. The bullish case rests on EVX-01's Phase 2b melanoma data and the company's AI platform, while the principal obstacles are clinical uncertainty, a limited cash runway, dilution risk, and the stock's demonstrated small-cap volatility. With no bearish targets published but a wide bullish-to-cautious spread, investors should watch clinical readouts and financing news closely. Nothing here guarantees the target will be reached.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EVAX has been loosely correlated with GNPX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EVAX jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To EVAX | 1D Price Change % | ||
|---|---|---|---|---|
| EVAX | 100% | +8.70% | ||
| GNPX - EVAX | 40% Loosely correlated | -1.43% | ||
| CYPH - EVAX | 34% Loosely correlated | +16.60% | ||
| SANA - EVAX | 33% Poorly correlated | +1.28% | ||
| VYGR - EVAX | 32% Poorly correlated | +8.43% | ||
| NCEL - EVAX | 31% Poorly correlated | -4.50% | ||
More | ||||